BioSpace News Archive

Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced data from preclinical studies of XTX301, an engineered tumor-selective interleukin-12 (IL-12) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with minimal systemic activity.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced additional clinical data for its tumor infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, provided a business update and announced its financial results and operational highlights for the quarter ended September 30, 2021.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), today provided a business update regarding the status of the Company’s various clinical research programs and reported its financial results for the quarter ended September 30, 2021.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported preclinical data from the company’s newly selected core inhibitor candidate, ABI-4334 (4334), and clinical results from the Phase 1a study of ABI-H3733 (3733) in healthy volunteers at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting™

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent clinical and development pipeline progress.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced new data from the Phase 3 PEDFIC 1 study and PEDFIC 2 long-term extension study of Albireo’s product, Bylvay (odevixibat), and first data from preclinical studies of cholestatic and viral disease product candidate, A2342.

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Applied Genetic Technologies Corporation announced the presentation of additional analyses and conclusions from previously reported data from the Company’s ongoing Phase 1/2 study of AGTC-501 at the American Academy of Ophthalmology 2021 Annual Meeting being held today in New Orleans, Louisiana by Dr. Robert Sisk.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a new, blinded, post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) in biopsy-confirmed patients with non-alcoholic steatohepatitis (NASH).